Schellenberg Wittmer advises Dr. Reddy's Laboratories Ltd., a global pharmaceutical company headquartered in Hyderabad (India) listed at BSE, NSE and NYSE, on the acquisition from Haleon plc of Northstar Switzerland SARL, a Swiss company holding Haleon's global business of consumer healthcare brands in the Nicotine Replacement Therapy (NRT) category outside of the United States, including Nicotinell, a global leader in the NRT category with an extensive footprint in over 30 markets spanning Europe, Asia including Japan, and Latin America. The total consideration amounts to £500 million, with an upfront cash payment of £458 million and performance-based contingent payments of up to £42 million.